MCRB
Seres Therapeutics Inc
$5.46
Earnings Summary
Revenue | $5.72Mn |
Net Profits | $-35.47Mn |
Net Profit Margins | -620.23% |
Highlights
Seres Therapeutics Inc’s revenue fell -30.17% since last year same period to $5.72Mn in the Q1 2021. On a quarterly growth basis, Seres Therapeutics Inc has generated -67.44% fall in its revenue since last 3-months.
Seres Therapeutics Inc’s net profit fell -78.39% since last year same period to $-35.47Mn in the Q1 2021. On a quarterly growth basis, Seres Therapeutics Inc has generated -94.31% fall in its net profits since last 3-months.
Seres Therapeutics Inc’s net profit margin fell -155.48% since last year same period to -620.23% in the Q1 2021. On a quarterly growth basis, Seres Therapeutics Inc has generated -496.85% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Seres Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Current Year | -0.45 |
Highlights
Seres Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a 4.26% jump from last quarter’s estimates.
Seres Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.45.
Key Ratios
Key ratios of the Seres Therapeutics Inc post its Q4 2022 earnings
Return on Assets (ROA) | -0.44 |
Return on Equity (ROE) | -3.52 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Seres Therapeutics Inc’s return on assets (ROA) stands at -0.44.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Seres Therapeutics Inc’s return on equity (ROE) stands at -3.52.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2020-11-09 | -0.25 | -0.36 | -44% |
2021-03-02 | -0.28 | -0.23 | 17.86% |
2020-05-07 | -0.28 | -0.28 | 0% |
2020-07-28 | -0.26 | -0.28 | -7.69% |
Company Information
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
Organisation | Seres Therapeutics Inc |
Headquarters | 200 Sidney Street, Cambridge, MA, United States, 02139 |
Employees | 431 |
Industry | Health Technology |
CEO | Eric Shaff |
